Retatrutide, developed by Soma Chems , is receiving significant attention as a novel therapy for metabolic control . This unique medication integrates the mechanism of a GLP-1 receptor agonist and a GIP receptor agonist , aiming to simply promote metabolic improvements but also target related metabolic issues . Initial clinical studies have demonst